Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tyler Flaningham

Psychiatry Carmel, IN Medical Doctor

NPI 1538369053 CMS profile 114945

703 Pro-Med Ln, Carmel, IN 46032

Open in the dashboard

General payments

$7,372

450 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tyler Flaningham of Carmel, IN is reported in the CMS Open Payments database as having received $7,372 across 450 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $829 37
2024 General $1,912 72
2023 General $1,499 108
2022 General $1,114 117
2021 General $230 15
2020 General $434 15
2019 General $1,354 86

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tyler Flaningham
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Tyler Flaningham were reported at $829. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Tyler Flaningham Psychiatry median Middle half National median
2019 $1,354 $184 $59–$605 $163
2020 $434 $119 $36–$372 $114
2021 $230 $143 $43–$576 $132
2022 $1,114 $153 $50–$590 $149
2023 $1,499 $170 $56–$651 $160
2024 $1,912 $179 $57–$673 $164
2025 $829 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,319 56 payments
  2. Supernus Pharmaceuticals, Inc. $846 134 payments
  3. Ironshore Pharmaceuticals Inc. $605 29 payments
  4. ITI, Inc. $440 21 payments
  5. Vanda Pharmaceuticals Inc. $391 17 payments
  6. Neurocrine Biosciences, Inc. $368 12 payments
  7. Janssen Pharmaceuticals, Inc $364 19 payments
  8. Teva Pharmaceuticals USA, Inc. $360 19 payments
  9. Otsuka America Pharmaceutical, Inc. $320 8 payments
  10. Alkermes, Inc. $281 13 payments
  11. Other $2,078 122 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,372 450 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR Neuroscience $1,212 51 payments
  2. JORNAY PM $507 23 payments
  3. QELBREE Psychology $438 118 payments
  4. CAPLYTA $423 20 payments
  5. Qelbree Viloxazine Hydrochloride $408 16 payments
  6. HETLIOZ $391 17 payments
  7. FANAPT $391 17 payments
  8. VRAYLAR Neuroscience $350 20 payments
  9. SPRAVATO $335 17 payments
  10. REXULTI $295 7 payments
  11. Other $4,388 237 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

450 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record